References
- Kortykowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, openlabel, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injections in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;11:2836-48
- Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;9:1498-505
- Stocki K, Ory C, Vanderplas A, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin 2007;23:133-46
- Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diab Care 2004;27:2495-7
- Bohannon NJV, Ohannesian JP, Burdan AL, et al. Patient and physician satisfaction with the Humulin/Humalog pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther 2000;22:1049-67
- Rosak C, Burkard G, Hoffmann JA, et al. Metabolic effect and acceptance of an insulin pen treatment in 20,262 diabetic patients. Diab Nutr Metab 1993;6:139-45
- Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Primary Care Diabetes 2010;4(Suppl 1):S11-18
- Frid A, Ostman J, Linde B. Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care 1990;13:473-7
- McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients’ perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diab Tech Ther 2009;11:195-201
- Strauss K, Hannet I, McGonigle J, et al. Ultra-short (5 mm) insulin needles: trial results and clinical recommendations. Pract Diab Intl 1999;16:218-22
- Nagai Y, Ohshige T, Arai K, et al. Comparison between shorter straight and thinner microtapered insulin injection needles. Diabetes Technol Ther 2013;15:550-5
- Miwa T, Itoh R, Kobayashi T, et al. Comparison of the effects of a new 32-gauge × 4-mm pen needle and a 32-gauge × 6-mm pen needle on glycemic control, safety, and patient ratings in Japanese adults with diabetes. Diabetes Technol Ther 2012;14:1084-90
- Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther 2004;26:1663-78
- Gibney MA, Arce CH, Byron KJ, et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin 2010;26:1519-30
- Hirsch LJ, Gibney MA, Albanese J, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin 2010;26:1531-41
- Hom FG, Ettinger B, Lin MJ. Comparison of serum fructosamine vs glycohemoglobin as measures of glycemic control in a large diabetic population. Acta Diabetol 1998;35:48-51
- Hom F. Fructosamine, hemoglobin A1c, and measures of diabetic control. Diab Tech Ther 1999;1:443-5
- Smaldone A. Glycemic control and hemoglobinopathy: when A1c may not be reliable. Diab Spectrum 2008;21:46-9
- Ross SA, Jamal R, Leiter LA, et al. Evaluation of 8mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diab Intl 1999;16:145-8